Drug safety on trial - Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval

被引：16

作者：

Greener, M

机构：

来源：

关键词：

D O I：

10.1038/sj.embor.7400353

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：202 / 204

页数：3

共 7 条

[1] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

[2]

Eland IA, 1999, BRIT J CLIN PHARMACO, V48, P623

[3]

Frantz S, 2005, NAT REV DRUG DISCOV, V4, P5, DOI 10.1038/nrd1629

[4]

Harris Gardiner, 2004, N Y Times Web, pA19

[5] Cutting the cost of drug development? [J].

Rawlins, MD .

[6] Failing the public health - Rofecoxib, Merck, and the FDA [J].

Topol, EJ .

[7]

2004, PHARM BUSINESS 1202, P1